Please use this identifier to cite or link to this item:
PHOTOBIOMODULATION REDUCES THE CYTOKINE STORM SYNDROME ASSOCIATED WITH COVID-19 IN THE ZEBRAFISH MODEL
Cytokine Release Syndrome
Oxidative Stress
rSpike
Photobiomodulation
Low-Level Light Therapy
Zebrafish
Síndrome da Liberação de Citocina
Estresse Oxidativo
COVID-19
Terapia com Luz de Baixa Intensidade
Peixe-Zebra
Author
Affilliation
Abstract
Although the exact mechanism of the pathogenesis of coronavirus SARS-CoV-2 (COVID-19) is not fully understood, oxidative stress and the release of pro-inflammatory cytokines have been highlighted as playing a vital role in the pathogenesis of the disease. In this sense, alternative treatments are needed to reduce the level of inflammation caused by COVID-19. Therefore, this study aimed to investigate the potential effect of red photobiomodulation (PBM) as an attractive therapy to downregulate the cytokine storm caused by COVID-19 in a zebrafish model. RT-qPCR analyses and protein–protein interaction prediction among SARS-CoV-2 and Danio rerio proteins showed that recombinant Spike protein (rSpike) was responsible for generating systemic inflammatory processes with significantly increased levels of pro-inflammatory (il1b, il6, tnfa, and nfkbiab), oxidative stress (romo1) and energy metabolism (slc2a1a and coa1) mRNA markers, with a pattern similar to those observed in COVID-19 cases in umans. On the other hand, PBM treatment was able to decrease the mRNA levels of these pro-inflammatory and oxidative stress markers compared with rSpike in various tissues, promoting an anti- inflammatory response. Conversely, PBM promotes cellular and tissue repair of injured tissues and significantly increases the survival rate of rSpike-inoculated individuals. Additionally, metabolomics analysis showed that the most-impacted metabolic pathways between PBM and the rSpike treated groups were related to steroid metabolism, immune system, and lipid metabolism. Together, our findings suggest that the inflammatory process is an incisive feature of COVID-19 and red PBM can be used as a novel therapeutic agent for COVID-19 by regulating the inflammatory response. Nevertheless, the need for more clinical trials remains, and there is a significant gap to overcome before clinical trials can commence.
Keywords
Cytokine StormCytokine Release Syndrome
Oxidative Stress
rSpike
Photobiomodulation
Low-Level Light Therapy
Zebrafish
DeCS
Tempestade de CitocinaSíndrome da Liberação de Citocina
Estresse Oxidativo
COVID-19
Terapia com Luz de Baixa Intensidade
Peixe-Zebra
Share